CURRENT MEDICAL RESEARCH AND OPINION, vol.20, no.11, pp.1759-1767, 2004 (SCI-Expanded)
Objective: In this study the effect of a specific glycoprotein)IIb/IIIa inhibitor, tirofiban [which also has antiplatelet activity on acute systemic inflammatory responses (III) during elective percutaneous coronary intervention (PCI)] was evaluated.